SCHEMBL14712893

SCHEMBL14712893

CCN1C(=O)NC(=O)/C(=C\C=C\c2ccco2)C1=O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 18/20 0.74
KMT2A Q03164 18/20 0.74
RECQL P46063 16/20 0.74
MAPT P10636 16/20 0.74
NPSR1 Q6W5P4 11/20 0.74
MAPK1 P28482 10/20 0.74
KDM4E B2RXH2 3/20 0.74
APEX1 P27695 3/20 0.74
TDP1 Q9NUW8 2/20 0.74
XBP1 P17861 2/20 0.74
USP2 O75604 1/20 0.74
POLB P06746 12/20 0.73
MITF O75030 9/20 0.73
L3MBTL1 Q9Y468 9/20 0.73
ALDH1A1 P00352 9/20 0.73
PKM P14618 6/20 0.73
HTT P42858 6/20 0.73
LMNA P02545 5/20 0.73
BLM P54132 4/20 0.73
HPGD P15428 6/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3471120 0.89 MEN1 (0.80) MEN1KMT2ARECQLMAPTNPSR1
SCHEMBL14712984 0.89 MEN1 (0.80) MEN1KMT2ARECQLMAPTNPSR1
SCHEMBL3471124 0.89 MEN1 (0.80) MEN1KMT2ARECQLMAPTNPSR1
SCHEMBL14713067 0.84 MEN1 (0.81) MEN1KMT2ARECQLMAPTNPSR1
SCHEMBL14712947 0.82 MEN1 (1.00) MEN1KMT2ARECQLMAPTNPSR1
SCHEMBL14712892 0.79 MAPT (0.72) MEN1KMT2ARECQLMAPTNPSR1
SCHEMBL16542997 0.78 DUSP3 (1.00) MEN1KMT2ARECQLMAPTNPSR1
SCHEMBL14712884 0.77 F2 (0.78) MEN1KMT2ARECQLMAPTNPSR1
SCHEMBL26458992 0.76 MEN1 (1.00) MEN1KMT2ARECQLMAPTNPSR1
SCHEMBL14712870 0.76 KMT2A (0.51) MEN1KMT2ARECQLMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
WO-2013024447-A1 COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAX MEN1 2410/4885KMT2A 2749/4885RECQL 1708/4885
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAK1 MEN1 1885/4885KMT2A 3262/4885RECQL 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.